Literature DB >> 31939162

Amyloid Oligomers, Protofibrils and Fibrils.

Mohammad Khursheed Siddiqi1, Nabeela Majid1, Sadia Malik1, Parvez Alam1, Rizwan Hasan Khan2.   

Abstract

Amyloid diseases are of major concern all over the world due to a number of factors including: (i) aging population, (ii) increasing life span and (iii) lack of effective pharmacotherapy options. The past decade has seen intense research in discovering disease-modifying multi-targeting small molecules as therapeutic options. In recent years, targeting the amyloid cascade has emerged as an attractive strategy to discover novel neurotherapeutics. Formation of amyloid species, with different degrees of solubility and neurotoxicity is associated with the gradual decline in cognition leading to dementia/cell dysfunction. Here, in this chapter, we have described the recent scenario of amyloid diseases with a great deal of information about the structural features of oligomers, protofibrils and fibrils. Also, comprehensive details have been provided to differentiate the degree of toxicity associated with prefibrillar aggregates. Moreover, a review of the technologies that aid characterisation of oligomer, protofibrils and fibrils as well as various inhibition strategies to overcome protein fibrillation are also discussed.

Entities:  

Keywords:  Alzheimer’ disease; Amyloid; Cell toxicity; Prefibrillar aggregates

Mesh:

Substances:

Year:  2019        PMID: 31939162     DOI: 10.1007/978-3-030-28151-9_16

Source DB:  PubMed          Journal:  Subcell Biochem        ISSN: 0306-0225


  2 in total

Review 1.  Neurometals in the Pathogenesis of Prion Diseases.

Authors:  Masahiro Kawahara; Midori Kato-Negishi; Ken-Ichiro Tanaka
Journal:  Int J Mol Sci       Date:  2021-01-28       Impact factor: 5.923

2.  Fas Apoptosis Inhibitory Molecule Blocks and Dissolves Pathological Amyloid-β Species.

Authors:  Hiroaki Kaku; Alexander V Ludlow; Michael F Gutknecht; Thomas L Rothstein
Journal:  Front Mol Neurosci       Date:  2021-12-14       Impact factor: 5.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.